Antifibrotická terapie a její indikace u intersticiální plicní fibrózy
| Title in English | Antifibrotic therapy and its indications for interstitial pulmonary fibrosis |
|---|---|
| Authors | |
| Year of publication | 2022 |
| Type | Article in Periodical |
| Magazine / Source | Vnitřní lékařství |
| MU Faculty or unit | |
| Citation | |
| Web | https://www.casopisvnitrnilekarstvi.cz/artkey/vnl-202204-0002_antifibrotic-therapy-and-its-indications-for-interstitial-pulmonary-fibrosis.php |
| Doi | http://dx.doi.org/10.36290/vnl.2022.045 |
| Keywords | idiopathic pulmonary fibrosis; nintedanib; pirfenidon; progressive fibrosing interstitial lung diseases |
| Description | Idiopathic pulmonary fibrosis and chronic fibrotic interstitial lung disease with progressive phenotype are characterized by fibrotic lung parenchyma. Current antifibrotic treatment does not affect pre-existing lung parenchyma fibrosis, but prevents fibrosis progression and reduces mortality by reducing fibrotization. This work summarizes fibrotic lung processes and their treatment options. © 2022, SOLEN s.r.o.. All rights reserved. |